ArticleStem cell reports2026
Rbm25 governs embryonic stem cell identity and fate through transcriptional regulation of pluripotency and epigenetic programs.
Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RBM5 Acts as a Tumor Suppressor in Breast Cancer Through Binding to G-quadruplexes in the BAP1 Gene Promoter to Activate Its Expression.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embryonic stem cells (ESCs) can self-renew and differentiate into somatic cells. They can also adopt a totipotent-like state and become 2-cell-like cells (2CLCs). However, how these progresses are regulated remains poorly understood. Here, we define a novel role for Rbm25 (RNA-binding motif protein 25), previously known as a splicing regulator, in the maintenance of ESC identity. Rbm25 is highly expressed in ESCs and is downregulated during differentiation. Deletion or depletion of Rbm25 impairs ESC self-renewal and differentiation and promotes the transition toward 2CLCs. Mechanistically, RBM25 occupies pluripotency- and DNA methylation-related gene promoters and directly regulates their expression, thereby governing the gene expression program and the epigenetic state of ESCs. Together, our data indicate that Rbm25 controls stem cell fate specification at the transcription level and therefore uncover a new role of Rbm25 as a transcriptional regulator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.